Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1398-1405

  Fukuno, Kenji ^a   Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Shibata, Yuhei ^a   Mabuchi, Ryoko ^a   Nakamura, Nobuhiko ^a   Kitagawa, Junichi ^a   Shimizu, Masahito ^a   Ito, Hiroyasu ^a   Saito, Kuniaki ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myeloid leukemia; Immunological tolerance; Indoleamine 2,3 dioxygenase; l tryptophan catabolism; Prognostic factor

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; BIOLOGICAL MARKER; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CYTOGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; AGED; CHROMOSOME ABERRATION; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PROGNOSIS; TANDEM REPEAT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHROMOSOME ABERRATIONS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOPHENOTYPING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84932080600     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.953150     Document Type: Article

References (44)

1. Mckenzie SB. Advances in understanding the biology and genetics of acute myeloid leukemia. Clin Lab Sci. 2005;18:28-37.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classif cation of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
3. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensif cation therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;14:204-213.
4. Miyawaki S, Tanimoto M, Kobayashi T, et al. No benef cial Effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999; 70: 97-104.
5. Mro'zek K, Heinonen K, de la Chapelle A, et al. Clinical signif cance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
6. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976-982.
7. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-3080.
8. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469-473.
9. Munn DH, Shafzadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372.
10. Murray HW, Szuro-Sudol A, Wellner D, et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 1989;57:845-849.
11. Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001;31:2313-2318.
12. Fujigaki H, Saito K, Fujigaki S, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2, 3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic Effect of several proinfammatory cytokines. J Biochem 2006;139:655-662.
13. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002;196:459-468.
14. Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-1696.
15. Yoshikawa T, Hara T, Tsurumi H, et al. Serum concentration of L-kynurenine predicts the clinical outcome of patients with dif use large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010;84:304-309.
16. Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine2, 3-dioxygenase in tumor tissue indicates prognosis in patients with dif use large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011; 90: 409-416.
17. Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine2, 3-dioxygenase expression and serum kynurenine concentrations in patients with difuse large B-cell lymphoma. Leuk Lymphoma 2012;53:1143-1145.
18. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S, Campo E, Harris NL, editors. WHO classif cation of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp 124-126.
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
20. Hoshi M, Saito K, Hara A, et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 2010;185:3305-3312.
21. Miyazaki Y, Kuriyama K, Miyawaki S, et al.; Japan Adult Leukaemia Study Group. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 2003;120:56-62.
22. Tsurumi H, Kanemura N, Hara T, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the ef cacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol 2007;133:547-553.
23. Kanemura N, Tsurumi H, Kasahara S, et al. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematol Oncol 2008;26:33-38.
24. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
25. Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al. High INDO (indoleamine 2, 3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008;93:1894-1898.
26. Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 2006;108:4118-4125.
27. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-1561.
28. Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333-1339.
29. Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134:1247-1253.
30. Curti A, Aluigi M, Pandolf S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase. Leukemia 2007;21:353-355.
31. Curti A, Pandolf S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25 + T regulatory cells. Blood 2007;109:2871-2877.
32. Muller AJ, Du Hadaway JB, Donover PS, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-319.
33. Yoshida N, Ino K, Ishida Y, et al. Overexpression of indoleamine 2, 3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 2008;14:7251-7259.
34. Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009;115:185-192.
35. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
36. Jeong YI, Jung ID, Lee JS, et al. (-)-Epigallocatechin gallate suppresses indoleamine 2, 3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem Biophys Res Commun 2007; 354: 1004-1009.
37. Cheng CW, Shieh PC, Lin YC, et al. Indoleamine 2, 3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem 2010;58:887-894.
38. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002;42:25-54.
39. Rodriguez SK, Guo W, Liu L, et al. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006;118:1635-1644.
40. Han C. Screening of anticarcinogenic ingredients in tea polyphenols. Cancer Lett 1997;114:153-158.
41. Surh YJ, Chun KS, Cha HH, et al. Molecular mechanism sunderlying chemopreventive activities of anti-inf ammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001;480-481:243-268.
42. Aggarwal BB, Shishodia S, Sandur SK, et al. Inf ammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-1621.
43. Shirakami Y, Shimizu M, Tsurumi H, et al. EGCG and polyphenon E attenuate inf ammation-related mouse colon carcinogenesis induced byAOM and DSS. Mol Med Rep 2008;l:355-361.
44. Ogawa K, Hara T, Shimizu M, et al. Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2, 3-dioxygenase. Cancer Sci 2012; 103: 951-958.